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Abstract The goal of this work was to propose a possible mechanism for the
butyrylcholinesterase activation by 2,4,6-trinitrotoluene (TNT), 3,3-dimethylbutyl-N-n-
butylcarbamate (1), and 2-trimethylsilyl-ethyl-N-n-butylcarbamate (2). Kinetically, TNT,
and compounds 1 and 2 were characterized as the nonessential activators of butyrylcho-
linesterase. TNT, and compounds 1 and 2 were hydrophobic compounds and were proposed
to bind to the hydrophobic activator binding site, which was located outside the active site
gorge of the enzyme. The conformational change from a normal active site gorge to a more
accessible active site gorge of the enzyme was proposed after binding of TNT, and
compounds 1 and 2 to the activator binding site of the enzyme. Therefore, TNT, and
compounds 1 and 2 may act as the excess of butyrylcholine in the substrate activator for the
butyrylcholinesterase catalyzed reactions.
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Introduction
Butyrylcholinesterase (BChE, EC 3.1.1.8) is a serine hydrolase related to acetylcholines-
terase (AChE, EC 3.1.1.7). Unlike AChE, which plays a vital role in the central and
peripheral nervous systems, the physiological function of BChE remains unclear [1–4].
Despite having no identified endogenous substrate, BChE plays a key role in detoxification
by degrading esters like succinylcholine and cocaine [5]. The X-ray structures of BChE and
BChE–inhibitor complex have been recently reported [6, 7]. Similar to AChE [8–11], the
active site of BChE contains (a) an esteratic site comprised of the catalytic triad Ser198-
His438-Glu325, which is located at the bottom of the gorge [6, 7]; (b) an oxyanion hole
Appl Biochem Biotechnol (2008) 150:337–344
DOI 10.1007/s12010-008-8295-z
S.-Y. Chiou
Division of Neurosurgery, Chung-Shan Medical University and Hospital, Taichung 402, Taiwan
Y.-G. Wu :G. Lin (*)
Department of Chemistry, National Chung-Hsing University, Taichung 402, Taiwan
e-mail: gilin@dragon.nchu.edu.tw
composed of Gly116, Gly117, and Ala199 that stabilizes the tetrahedral intermediate; (c) an
anionic substrate binding site (AS) composed of Trp82, where the quaternary ammonium
pole of butyrylcholine (BCh) and of various active site ligands binds through a preferential
interaction of quaternary nitrogens with the π electrons of aromatic groups; (d) an acyl
group binding site that binds the acyl or carbamyl group of substrate or inhibitor; and (e) a
peripheral anionic binding site composed of Phe278 [12], Tyr332 [13], and Asp70, which is
located at the entrance (mouth) of the active site gorge that may bind to the tacrine-based
hetero-bivalent ligands [12] and cage amines [14].
BChE-catalyzed reactions often show substrate activation at high substrate concen-
trations [15]. The kinetic evidence for substrate activation of BChE-catalyzed hydrolysis of
butyrylthiocholine has been observed by Tormos et al. [16]. However, no other activator
rather than substrates of BChE has been reported so far. Therefore, search for a substrate
analog that only displays as an activator but not as a substrate of BChE will illuminate the
understanding of substrate activation mechanism of the enzyme. The hydrophobic analogs
of butyrylcholine, 3,3-dimethylbutyl-N-n-butylcarbamate (1), and 2-trimethylsilyl-ethyl-N-
n-butylcarbamate (2) (Fig. 1) are synthesized for this purpose.
Nitro compounds such as nitroglycerin, 2,4,6-trinitrotoluene (TNT), picric acid, styphnic
acid, hexahydro-1,3,5-trinitrotriazocine (RDX), and octahydro-1,3,5,7-tetranitrotriazocine
(HMX; Fig. 1) are widely known as explosives [17]. Especially, TNT is hydrophobic and is
slightly soluble in water. TNT has been reported as an activator of lipase [18]. Therefore,
TNT is also chosen as a potential activator of BChE based on these characters.
Materials and Methods
Materials
Horse serum BChE, 5,5′-dithio-bis-2-nitrobenzoate (DTNB), and butyrylthiocholine
(BTCh) were obtained from Sigma (USA). All other chemicals were of the highest purity
available commercially. TNT was provided from Taiwan Army.
Synthesis of 3,3-Dimethylbutyl-N-n-butylcarbamate (1) and 2-trimethylsilyl-ethyl-N-n-
butylcarbamate (2)
3,3-Dimethylbutyl-N-n-butylcarbamate (1) and 2-trimethylsilyl-ethyl- N-n-butylcarbamate
(2) (Fig. 1) were synthesized from the condensation of 3,3-dimethylbutanol and 2-
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Fig. 1 Chemical structures of
TNT, and compounds 1 and 2
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(trimethylsilyl)ethanol, respectively, with 1.2 equivalents of n-butyl isocyanate in
tetrahydrofuran at 25 °C for 48 h (87% and 85% yield, respectively). The products were
purified by liquid chromatography (silica gel and hexane-ethyl acetate) and characterized
by 1H, 13C NMR, and high resolution mass spectra. 3,3-Dimethylbutyl-N-n-butylcarbamate
(1): 1H NMR (CDCl3, 300 MHz) δ/ppm 0.88 (t, J=6 Hz, 3H, ω-CH3), 0.89 (s, 9H, C
(CH3)3), 1.30 (sextet, J=6 Hz, 2H, γ-CH2), 1.44 (quintet, J=7 Hz, 2H, β-CH2), 1.50 (t, J=
7.6 Hz, 2H, CH2C(CH3)3), 3.12 (m, 2H, α-CH2), 4.07 (t, J=7 Hz, 2H, OCH2CH2C(CH3)3),
and 4.72 (s, NH). 13C NMR (CDCl3, 75.4 MHz, assignment from DEPT experiments)
δ/ppm 13.6 (ω-CH3), 19.8 (γ-CH2), 29.5 (C(CH3)3), 32.0 (β-CH2), 40.6 (OCH2CH2C
(CH3)3), 42.1 (α-CH2), 63.3 (OCH2CH2C(CH3)3), and 156.8 (carbamate C=O). 2-
Trimethylsilyl-ethyl-N-n-butylcarbamate (2): 1H NMR (CDCl3, 300 MHz) δ/ppm 0.11 (s,
9H, Si(CH3)3), 0.95 (t, J=6 Hz, 3H, ω-CH3), 1.34 (sextet, J=6 Hz, 2H, γ-CH2), 1.45
(quintet, J=7 Hz, 2H, β-CH2), 1.60 (t, J=7.6 Hz, 2H, CH2Si(CH3)3), 3.14 (m, 2H, α-CH2),
4.12 (t, J=6 Hz, 2H, OCH2CH2Si(CH3)3), and 4.68 (s, NH).
13C NMR (CDCl3, 75.4 MHz,
assignment from DEPT experiments) δ/ppm −1.5 (Si(CH3)3), 13.7 (ω-CH3), 17.7
(OCH2CH2Si(CH3)3), 19.8 (γ-CH2), 32.8 (β-CH2), 40.7 (α-CH2), 62.8 (OCH2CH2Si
(CH3)3), and 156.8 (carbamate C=O).
Instrumental Methods
All steady state kinetic data were obtained from an ultraviolet (UV)-visible spectropho-
tometer (Agilent 8453) with a cell holder circulated with a water bath.
Data Reduction
Origin (version 6.0) was used for linear and nonlinear least-squares curve fittings.
Enzyme Kinetics of BChE Activation
BChE-catalyzed hydrolysis of butyrylthiocholine chloride (BTCh; 0.1 mM) in the presence
of nitro compounds was followed continuously at 410 nm on a UV-visible spectrometer.
The temperature was maintained at 25.0 °C by a refrigerated circulating water bath. All
reactions were preformed in sodium phosphate buffer (1 ml, 0.1 M, pH 7.0) containing
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Fig. 2 Nonlinear least-squares
curve fittings of the Vmax, app/
Vmax value for the BChE-
catalyzed hydrolysis of BTCh
vs. activator 1 concentration
([A]) plot against Eq. 2. The
parameters of the fit were αKA=
18±4 μM and β=1.0023±0.0001
(R2=0.9815)
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NaCl (0.1 M), CH3CN (2% by volume), BTCh (0.0125, 0.025, 0.05, and 0.1 mM), DTNB
(same concentration as BTCh) with or without an activator (compound 1 or 2, or TNT; 0,
25, 50, 100, and 200 μM) according to Ellman’s method [19]. Requisite volumes of stock
solution of BTCh, DTNB, and an activator in acetonitrile were injected into reaction buffer
via a pipet. BChE was dissolved in sodium phosphate buffer (0.1 M, pH 7.0). TNT and
compounds 1 and 2 were characterized as the nonessential activators of the enzyme (Figs. 2
and 3, Scheme 1, and Table 1) [20]. Then, the Henri–Michaelis–Menten form the velocity
equation:
v=Vmax ¼ S½ = Km 1þ A½ =KAð Þ= 1þ b A½ =aKAð Þ þ S½  1þ A½ =aKAð Þ= 1þ b A½ =aKAð Þð Þ
ð1Þ
In Eq. 1, Vmax and Km were maximal velocity and Michaelis constant in the absence of an
activator, and KA is the activation constant in the presence of an activator. The Vmax and Km
values in the absence of an activator were 0.3223±0.005 AU/s and 110±30 μM,
respectively, obtained from nonlinear least-squares curve fittings of v vs. BTCh
concentration ([S]) plot against the Michaelis–Menten equation. At any activator
concentration:
Vmax;app

Vmax ¼ aKA þ b A½ ð Þ= aKA þ A½ ð Þ ð2Þ
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Fig. 3 Nonlinear least-squares
curve fittings of the Km, app/Km
value for the BChE-catalyzed
hydrolysis of BTCh vs. activator
1 concentration ([A]) plot against
Eq. 3. The parameters of the fit
were αKA=23±6 μM and α=
1.0029±0.0002 (R2=0.9745)
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Scheme 1 Kinetic scheme of
the nonessential activation of
BChE. S, E, and A are
substrate, enzyme, and activator,
respectively
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Km; app

Km ¼ aKA þ a A½ ð Þ= aKA þ A½ ð Þ ð3Þ
In Eqs. 2 and 3, Vmax, app and Km, app were apparent maximal velocity and apparent
Michaelis constant in the presence of an activator. The αKA and β values were then
obtained from the nonlinear least-squares curve fittings of the Vmax, app/Vmax values vs.
activator concentration ([A]) plot against Eq. 2 (Fig. 2). The αKA and α values were then
obtained from the nonlinear least-squares curve fittings of the Km, app/Km values vs.
activator concentration ([A]) plot against Eq. 3 (Fig. 3). Thus, the KA values could be
calculated from the αKA and α values (Table 1). Duplicate sets of data were collected for
each activator concentration.
Stop-time Assay for BChE Activation
For the control experiment (with an activator without incubation), BChE was incubated
alone for a period of time (t) at 25.0 °C before starting the reaction by addition of the
substrate BTCh (0.1 mM), DTNB (0.1 mM), and an activator (0.1 mM) to the enzyme
solution (Fig. 4). For the incubation of BChE with an activator experiment, BChE was
incubated with an activator (0.1 mM) for a period of time (t) at 25.0 °C before starting the
reaction by addition of the substrate BTCh (0.1 mM) and DTNB (0.1 mM) to the incubated
mixture. For the incubation of BChE with an activator and an inhibitor (edrophonium)
Table 1 The KA, α, and β values for the BChE activation by TNT, and compounds 1 and 2.
Compounds KA (μM) α
a βb
1 21±8 1.0029±0.0002 1.0023±0.0001
2 32±8 1.0060±0.0007 1.0052±0.0004
TNT 100±30 1.008±0.003 1.007±0.002
a Obtained from the nonlinear least-squares curve fittings of the Km, app/Km values vs. [A] plot against Eq. 3
(Fig. 3)
b Obtained from the nonlinear least-squares curve fittings of the Vmax, app/Vmax values and vs. [A] plot against
Eq. 2 (Fig. 2)
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Fig. 4 Stop-time assay for
BChE-catalyzed hydrolysis of
BTCh in the presence of activator
1 with or without incubation of
the enzyme with activator 1 or
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experiment, BChE was incubated with an activator (0.1 mM) and edrophonium (0.1 mM)
for a period of time (t) at 25.0 °C before starting the reaction by addition of the substrate
BTCh (0.1 mM) and DTNB (0.1 mM) to the incubated mixture. The initial velocity (v) of
the reaction was calculated from the time course. All the other procedures were similar to
those described in the Enzyme kinetics of BChE activation part.
Results
TNT, and compounds 1 and 2 are characterized as the nonessential activators [20] of BChE
(Figs. 2 and 3, Scheme 1, Table 1, and Eq. 1). Thus, the dissociation constant for activation
(or activation constant), αKA and the α value are determined from nonlinear least-squares
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Fig. 5 Schematic representation of the nonessential activation of BChE by TNT, compounds 1 or 2 in the
presence of substrate, BTCh. The notation is the same with that of Scheme 1. TNT, and compounds 1 and 2
may induce a conformational change of the enzyme. The activator may bind to the activator binding site of
the enzyme, which is located outside the active site like the co-lipase binding site to lipase [19, 20]
342 Appl Biochem Biotechnol (2008) 150:337–344
curve fittings of the plot of the Vmax, app/Vmax values on [A] against Eq. 2 (Fig. 2 and
Table 1). On the other hand, αKA and the β value can be determined from nonlinear least-
squares curve fittings of the plot of the Km, app/Km values on [A] against Eq. 3 (Fig. 3 and
Table 1). That all β and α values are slightly more than one (Table 1) indicates that TNT,
and compounds 1 and 2 are characterized as the nonessential activators of BChE. From the
stop-time assay, TNT, and compounds 1 and 2 are confirmed as activators of BChE (Fig. 4).
Discussion
Since TNT, and compounds 1 and 2 are characterized as the nonessential activators of
BChE (Table 1), TNT, and compounds 1 and 2may bind outside the active site gorge of
BChE like the co-lipase binding site of lipase [21, 22] (Fig. 5). Then, TNT, and compounds
1 and 2 may induce a conformational change of BChE and activate the reaction (Fig. 5).
Thus, the substrate activation of BChE may act like the nonessential activator of the
enzyme by binding extra substrate outside the active site of the enzyme and activating the
enzyme.
The KA value for BChE activation by ATCh has been calculated to be 3.5 mM [16]. In
this study, the KA values for BChE activations by TNT, and compounds 1 and 2 are
calculated to be 100, 21, and 32 μM, respectively (Figs. 2 and 3, and Table 1). Therefore,
TNT, and compounds 1 and 2 are much potent activators than ATCh. On the other hand, the
β value of 2.6 has been reported for the BChE activation by ATCh [16], which is much
higher than the β values from this study.
Structurally, the hydrophilic active site of BChE is too hydrophilic to accept
hydrophobic compounds like TNT, and compounds 1 and 2. On the other hand, the
activator binding site of BChE is outside the active site gorge and is similar to the catalytic
site in size (Fig. 4) since huge, bulky compounds such as cage compounds [14], RDX, and
HMX are not activators of the enzyme (data not shown). At present, we find that only
small, hydrophobic molecules such as TNT, and compounds 1 and 2 are the non-essential
activators of BChE.
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